Sabine D. Brookman-May, Senior Vice President and Therapeutic Area Head Urologic Oncology at Aura Biosciences, shared on X:
“Impressive data presented by Joe Jacob from the Sunrise1 study with TAR200 in HR BCG unresponsive NMIBC CIS +/- papillary disease:
- 82.4% CR rate
- 25.8 months median DOR
- 52.9% of responses lasting more than 1 year “
In this post, Sabine D. Brookman-May spotlighted new data presented by Joe Jacob from the Sunrise1 study evaluating TAR200 in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The study reported a clinical complete response (CR) rate of 82.4%, a median duration of response (DOR) of 25.8 months, and over half of the responses lasting beyond one year—underscoring the therapeutic potential of TAR200 in a difficult-to-treat NMIBC population.
